New combo tackles tough ovarian cancer: early trial sees immune clues
NCT ID NCT05053750
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 33 times
Summary
This early-phase pilot study tested whether adding zoledronic acid to standard chemotherapy (paclitaxel and bevacizumab) could change immune cells called macrophages in women with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Only 14 women who had already tried 1-2 other treatments for recurrence took part. The main goal was to measure immune cell counts, not to cure or control the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.